Telephone
1.952.818.8400
Address
400 Gateway Boulevard Burnsville, MN 55337
Description
Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The firm offers the Advantage-MR EP Recorder/Stimulator system, an electrophysiology amplifier and recording system with integrated cardiac stimulator, Vision-MR Ablation Catheter, which is used as an indication for treating type I atrial flutter, and Vision-MR Dispersive Electrode, an ablation dispersive electrode that is used to minimize eddy currents induced on the conductive pads during MR scanning. It also performs contract research, as well as licenses its intellectual property for use in implantable devices. The company was founded by Steven Wedan in 2006 and is headquartered in Burnsville, MN.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.4 - 0.65
Trade Value (12mth)
AU$14,099.00
1 week
3.92%
1 month
1.44%
YTD
-0.5%
1 year
-11.01%
All time high
2.85
EPS 3 yr Growth
-14.70%
EBITDA Margin
%
Operating Cashflow
-$13m
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
191m
HALO Sector
Healthcare
Next Company Report Date
19-Feb-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
29 August 24 |
Results of Meeting
×
Results of Meeting |
28 August 24 |
Appendix 4D and Half Year Report & Accounts
×
Appendix 4D and Half Year Report & Accounts |
28 August 24 |
Imricor releases Half Year Results for 1H 2024
×
Imricor releases Half Year Results for 1H 2024 |
28 August 24 |
H1 FY24 Results Investor Presentation
×
H1 FY24 Results Investor Presentation |
13 August 24 |
Imricor Pauses TGA Process to Wait for 2nd Gen Catheter
×
Imricor Pauses TGA Process to Wait for 2nd Gen Catheter |
08 August 24 |
FY24 1H Results Webinar Notification
×
FY24 1H Results Webinar Notification |
08 August 24 |
Release from Voluntary Escrow
×
Release from Voluntary Escrow |
08 August 24 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
07 August 24 |
First Patient Treatment in the U.S. in the VISABL-AFL Trial
×
First Patient Treatment in the U.S. in the VISABL-AFL Trial |
06 August 24 |
Appendix 3X - Jeffrey Leighton
×
Appendix 3X - Jeffrey Leighton |
31 July 24 |
Imricor Q2 CY24 Quarterly Activities Report and Appendix 4C
×
Imricor Q2 CY24 Quarterly Activities Report and Appendix 4C |
31 July 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
26 July 24 |
Application for quotation of securities - IMR
×
Application for quotation of securities - IMR |
26 July 24 |
Cleansing Notice
×
Cleansing Notice |
19 July 24 |
Imricor Successfully Raises A$35 Million via Placement
×
Imricor Successfully Raises A$35 Million via Placement |
19 July 24 |
Equity Raising Presentation
×
Equity Raising Presentation |
19 July 24 |
Proposed issue of securities - IMR
×
Proposed issue of securities - IMR |
17 July 24 |
Trading Halt
×
Trading Halt |
16 July 24 |
Release from Voluntary Escrow
×
Release from Voluntary Escrow |
01 July 24 |
Imricor Completes Capital Equipment Installation at CHUV
×
Imricor Completes Capital Equipment Installation at CHUV |
28 June 24 |
Successful Completion of Second Case by Dubrava
×
Successful Completion of Second Case by Dubrava |
26 June 24 |
Imricor Wins New Customer in Hungary
×
Imricor Wins New Customer in Hungary |
21 June 24 |
Imricor Commences VISABL-AFL Trial for US FDA Approval
×
Imricor Commences VISABL-AFL Trial for US FDA Approval |
20 June 24 |
Commencement of Procedures at Dubrava University Hospital
×
Commencement of Procedures at Dubrava University Hospital |
13 June 24 |
Notification of cessation of securities - IMR
×
Notification of cessation of securities - IMR |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.